What exactly is Alzheimer’s disease, and how common is it? A: Alzheimer’s disease is a neurodegenerative disease that causes dementia. It is caused in part by the accumulation of abnormally folded ...

Unfortunately, medical treatments for Alzheimer’s disease and dementia have remained minimal for over 25 years, and with a ...

Discover breaking news detailing why the NHS will not cover two new Alzheimer’s drugs due to the high annual costs.

Dr. Nicholas Milano of Medical University of SC says medications such as Lecanemab and donanemab give Alzheimer's patients ...

The UK’s National Institute for Health and Care Excellence (Nice) has declined to recommend two new Alzheimer’s drugs for ...

New immunotherapy drugs offer some hope in the fight against Alzheimer's disease but they're too pricey for the NHS ...

To no great surprise, the U.K.’s health technology assessment body has found that the benefits of the first two approved Alzheimer’s disease drugs are too small to justify the costs. Neither Kisunla ...

To no great surprise, the U.K.’s health technology assessment body has found that the benefits of the first two approved Alzheimer’s disease drugs are too small to justify the costs. Neither Kisunla ...

Donanemab, developed by the pharmaceutical company Lilly, is given to patients via an intravenous drip once every four weeks. Lecanemab, developed by Eisai, is also given this way but fortnightly.

The fact is, even if donanemab and lecanemab were made available on the NHS tomorrow, too many patients wouldn’t be able to access them because the health system isn’t ready to deliver them ...

Donanemab and lecanemab are targeted antibody drugs that slow down the early stages of Alzheimer’s. They represent a huge step forward in research because they target a known cause of the disease, ...